Meta-analysis of probiotics for the treatment of irritable bowel syndrome

World Journal of Gastroenterology

Volumn 14, Issue 17, 2008, Pages 2650-2661

  McFarland, Lynne V ^a,b   Dublin, Sascha ^c  

^a VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c CENTER FOR HEALTH STUDIES   (United States)

Author keywords

Irritable bowel syndrome; Meta analysis; Probiotics

Indexed keywords

PLACEBO; PROBIOTIC AGENT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ANGINA PECTORIS; ANXIETY; BACTERIAL STRAIN; BLOATING; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFICACY; DRUG USE; ENTEROPATHY; EPISTAXIS; FLATULENCE; HUMAN; IRRITABLE COLON; MEDLINE; META ANALYSIS; METHODOLOGY; NONHUMAN; RANDOMIZED CONTROLLED TRIAL; REVIEW; SCORING SYSTEM; SENSITIVITY ANALYSIS; SIDE EFFECT; SYMPTOM; SYSTEMATIC REVIEW; TASTE AVERSION; TREATMENT OUTCOME; GASTROINTESTINAL TRACT; MICROBIOLOGY;

GASTROINTESTINAL TRACT; HUMANS; IRRITABLE BOWEL SYNDROME; PROBIOTICS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 49649088887     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.2650     Document Type: Review

References (74)

1. Cain KC, Headstrom P, Jarrett ME, Motzer SA, Park H, Burr RL, Surawicz CM, Heitkemper MM. Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 124-132
2. Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Initial poor quality of life and new onset of dyspepsia: results from a longitudinal 10-year follow-up study. Gut 2007; 56: 321-327
3. Cremonini F, Talley NJ. Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am 2005; 34: 189-204
4. Saito YA, Cremonini F, Talley NJ. Association of the 1438G/A and 102T/C polymorphism of the 5-HT2A receptor gene with irritable bowel syndrome 5-HT2A gene polymorphism in irritable bowel syndrome. J Clin Gastroenterol 2005; 39: 835; author reply 835-836
5. Spiller R, Aziz Q, Creed F, Emmanuel A, Houghton L, Hungin P, Jones R, Kumar D, Rubin G, Trudgill N, Whorwell P. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007; 56: 1770-1798
6. Ruigomez A, Garcia Rodriguez LA, Panes J. Risk of irritable bowel syndrome after an episode of bacterial gastroenteritis in general practice: influence of comorbidities. Clin Gastroenterol Hepatol 2007; 5: 465-469
7. Agrawal A, Whorwell PJ. Irritable bowel syndrome: diagnosis and management. BMJ 2006; 332: 280-283
8. Cremonini F, Talley NJ. Treatments targeting putative mechanisms in irritable bowel syndrome. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 82-88
9. Quigley EM, Flourie B. Probiotics and irritable bowel syndrome: a rationale for their use and an assessment of the evidence to date. Neurogastroenterol Motil 2007; 19: 166-172
10. Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007; 42 Suppl 17: 41-47
11. Lin HC. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA 2004; 292: 852-858
12. Malinen E, Rinttila T, Kajander K, Matto J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373-382
13. Andresen V, Baumgart DC. Role of probiotics in the treatment of irritable bowel syndrome: potential mechanisms and current clinical evidence. Inter J Probiotics Prebiotics 2006; 1: 11-18
14. McFarland LV. Normal flora: diversity and functions. Microb Ecol Health Dis 2000; 12: 193-207
15. Elmer GW, McFarland LV, McFarland M. Introduction. Chapter 1. In: The Power of Probiotics: Improving Your Health with Beneficial Microbes., Binghamton, New York: Haworth Press, 2007: 3-5
16. McCarthy J, O'Mahony L, O'Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, Fitzgibbon J, O'Sullivan GC, Kiely B, Collins JK, Shanahan F. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003; 52: 975-980
17. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 541-551
18. Verdu EF, Bercik P, Verma-Gandhu M, Huang XX, Blennerhassett P, Jackson W, Mao Y, Wang L, Rochat F, Collins SM. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 2006; 55: 182-190
19. Szajewska H, Ruszczynski M, Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr 2006; 149: 367-372
20. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812-822
21. McFarland LV, Elmer GW and McFarland M. Meta-analysis of Probiotics for the Prevention and Treatment of Acute Pediatric Diarrhea. Internl J Probiotics Prebiotics 2006; 1: 63-76
22. McFarland LV. Meta-analysis of probiotics for the prevention of traveler's diarrhea. Travel Med Infect Dis 2007; 5: 97-105
23. Kuhbacher T, Ott SJ, Helwig U, Mimura T, Rizzello F, Kleessen B, Gionchetti P, Blaut M, Campieri M, Folsch UR, Kamm MA, Schreiber S. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006; 55: 833-841
24. Mimura T, Rizzello F, Helwig U, Poggioli G, Schreiber S, Talbot IC, Nicholls RJ, Gionchetti P, Campieri M, Kamm MA. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 108-114
25. Shaw RL, Booth A, Sutton AJ, Miller T, Smith JA, Young B, Jones DR, Dixon-Woods M. Finding qualitative research: an evaluation of search strategies. BMC Med Res Methodol 2004; 4: 5
26. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ 1997; 315: 1533-1537
27. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. QUOROM Group. Br J Surg 2000; 87: 1448-1454
28. Lim B, Manheimer E, Lao L, Ziea E, Wisniewski J, Liu J, Berman B. Acupuncture for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006; CD005111
29. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression--an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313: 253-258
30. Clarke M, Oxman AD, eds. Analyzing and Presenting Results: Cochrane Reviewers' Handbook 4.2 (updated November 2002- Section 8.) In: the Cochrane Library. Oxford: Update Software; 2003, issue 1, cited January 23, 2008. Available from: URL: http://www.cochrane.org/resources/ handbook/index.htm
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188
32. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634
33. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101
34. Sutton AJ, Duval SJ, Tweedie RL, Abrams KR, Jones DR. Empirical assessment of effect of publication bias on meta-analyses. BMJ 2000; 320: 1574-1577
35. Whorwell PJ, Altringer L, Morel J, Bond Y, Charbonneau D, O'Mahony L, Kiely B, Shanahan F, Quigley EM. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006; 101: 1581-1590
36. Adler SN. The probiotic agent Escherichia coli M-17 has a healing effect in patients with IBS with proximal inflammation of the small bowel. Dig Liver Dis 2006; 38: 713
37. Bazzocchi G, Gionchetti P, Almerigi PF, Amadini C, Campieri M. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Dig Liver Dis 2002; 34 Suppl 2: S48-S53
38. Brigidi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001; 152: 735-741
39. Colecchia A, Vestito A, La Rocca A, Pasqui F, Nikiforaki A, Festi D. Effect of a symbiotic preparation on the clinical manifestations of irritable bowel syndrome, constipation-variant. Results of an open, uncontrolled multicenter study. Minerva Gastroenterol Dietol 2006; 52: 349-358
40. Drisko J, Bischoff B, Hall M, McCallum R. Treating irritable bowel syndrome with a food elimination diet followed by food challenge and probiotics. J Am Coll Nutr 2006; 25: 514-522
41. Fan YJ, Chen SJ, Yu YC, Si JM, Liu B. A probiotic treatment containing Lactobacillus, Bifidobacterium and Enterococcus improves IBS symptoms in an open label trial. J Zhejiang Univ Sci B 2006; 7: 987-991
42. Astegiano M, Pellicano R, Terzi E, Simondi D, Rizzetto M. Treatment of irritable bowel syndrome. A case control experience. Minerva Gastroenterol Dietol 2006; 52: 359-363
43. Tsuchiya J, Barreto R, Okura R, Kawakita S, Fesce E, Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004; 5: 169-174
44. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002; 47: 2615-2620
45. Maupas JL, Champemont P, Delforge M. Treatment of irritable bowel syndrome. Double blind trial of Saccharomyces boulardii. Medecine Chirurgie Digestives 1983; 12: 77-79
46. Gade J, Thorn P. Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand J Prim Health Care 1989; 7: 23-26
47. Halpern GM, Prindiville T, Blankenburg M, Hsia T, Gershwin ME. Treatment of irritable bowel syndrome with Lacteol Fort a randomized, double-blind, cross-over trial. Am J Gastroenterol 1996; 91: 1579-1585
48. Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 1231-1238
49. O'Sullivan MA, O'Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomised double-blind placebo-controlled crossover study. Dig Liver Dis 2000; 32: 294-301
50. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001; 13: 1143-1147
51. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, Zinsmeister AR. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895-904
52. Bausserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 2005; 147: 197-201
53. Bittner AC, Croffut RM, Stranahan MC. Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin Ther 2005; 27: 755-761
54. Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005; 22: 387-394
55. Kim HJ, Vazquez Roque MI, Camilleri M, Stephens D, Burton DD, Baxter K, Thomforde G, Zinsmeister AR. A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005; 17: 687-696
56. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome - a double blind, placebo-controlled, randomized study. Clin Nutr 2005; 24: 925-931
57. Kim YG, Moon JT, Lee KM, Chon NR, Park H. The effects of probiotics on symptoms of irritable bowel syndrome. Korean J Gastroenterol 2006; 47: 413-419
58. Simren M, Syrous A, Lindh A, Abrahamsson H. Effects of lactobacillus plantarum 299v on symptoms and rectal sensitivity in patients with irritable bowel syndrome (IBS) - A randomized, double-blind controlled trial. Gastroenterology 2006; 130 Suppl 2: A600
59. Enck P, Menke G, Zimmermann K, Martens U, Klosterhalfen S. Effective probiotic therapy of the irritable bowel syndrome (IBS): A multi-center clinical trial with primary care physicians. Gastroenterology 2007; 132 Suppl 2: A79
60. Gawronska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007; 25: 177-184
61. D'haens GR, Kovacs G, Vergauwe P, Lonovics J, Bouhnik Y, Weiss W, Brunner H, Lavergne-Slove A, Di Stefano AF, Marteau P. A randomized controlled trial of the probiotic combination Lactibiane (R) in irritable bowel syndrome the Lactibiane (R) study group. Gastroenterology 2007; 132 Suppl 2: A371
62. Simren M, Lindh A, Sammelsson L, Olsson J, Posserud I, Strid H, Abrahamsson H. Effect of yoghurt containing three probiotic bacteria in patients with irritable bowel syndrome (IBS) - A randomized, double-blind, controlled trial. Gastroenterology 2007; 132 Suppl 2: A210
63. DiBaise JK, Lof J, Taylor K, Quigley EM. Lactobacillus plantarum 299V in the irritable bowel syndrome: A randomized, double-blind, placebo-controlled crossover study. Gastroenterology 2000; 118 Suppl 2: A3163
64. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004; 38: S104-S106
65. Long ZR, Yu CH, Yang Y, Wang HN, Chi XX. Clinical observation on acupuncture combined with microorganism pharmaceutical preparations for treatment of irritable bowel syndrome of constipation type. Zhongguo Zhenjiu 2006; 26: 403-405
66. Kajander K, Korpela R. Clinical studies on alleviating the symptoms of irritable bowel syndrome. Asia Pac J Clin Nutr 2006; 15: 576-580
67. Bittner AC, Croffut RM, Stranahan MC, Yokelson TN. Prescript-assist probiotic-prebiotic treatment for irritable bowel syndrome: an open-label, partially controlled, 1-year extension of a previously published controlled clinical trial. Clin Ther 2007; 29: 1153-1160
68. Moon JT, Kim HS, Park HJ. Effects of probiotics on the intestinal gas volume score and symptoms in patients with irritable bowel syndrome. A randomized double-blind placebo-controlled study. Gastroenterology 2007; 132 Suppl 2: A688
69. Porta N, Bonet C, Cobo E. Discordance between reported intention-to-treat and per protocol analyses. J Clin Epidemiol 2007; 60: 663-669
70. Salim A, Mackinnon A, Griffiths K. Sensitivity analysis of intention-to-treat estimates when withdrawals are related to unobserved compliance status. Stat Med 2008; 27: 1164-1179
71. Brittain E, Lin D. A comparison of intent-to-treat and per-protocol results in antibiotic non-inferiority trials. Stat Med 2005; 24: 1-10
72. Reichenbach S, Sterchi R, Scherer M, Trelle S, Burgi E, Burgi U, Dieppe PA, Juni P. Meta-analysis: chondroitin for osteoarthritis of the knee or hip. Ann Intern Med 2007; 146: 580-590
73. Camilleri M. Probiotics and irritable bowel syndrome: rationale, putative mechanisms, and evidence of clinical efficacy. J Clin Gastroenterol 2006; 40: 264-269
74. Bijkerk CJ, de Wit NJ, Muris JW, Jones RH, Knottnerus JA, Hoes AW. Outcome measures in irritable bowel syndrome: comparison of psychometric and methodological characteristics. Am J Gastroenterol 2003; 98: 122-127